Form 4 for AVTX Avalo Therapeutics, Inc.
Accepted 2025-11-17 00:00:00 ET · period of report 2025-11-14 · accession 0002013869-25-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-17 | 2025-11-14 | AVTX | Goldman Jonathan | Dir | S - Sale+OE | $14.34 | -11.4K | 0 | -100% | -$163.0K |
| D | 2025-11-17 | 2025-11-14 | AVTX | Goldman Jonathan | Dir | M - OptEx | $9.88 | +8,200 | 8,200 | New | +$81.0K |
| D | 2025-11-17 | 2025-11-14 | AVTX | Goldman Jonathan | Dir | M - OptEx | $0.00 | -8,200 | 16.4K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-14 | S | D | 8,200 | $14.35 | 0 | D | — | — | (F1) The reported securities were sold in multiple transactions at prices ranging from $14.02 to $14.60. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
| 2 | Common | Common Stock | 2025-11-14 | M | A | 8,200 | $9.88 | 8,200 | D | — | — | |
| 3 | Common | Common Stock | 2025-11-14 | S | D | 3,167 | $14.30 | 0 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2025-11-14 | M | D | 8,200 | $0.00 | 16,400 | D | $9.88 · — to 2034-08-13 | 8,200 Common Stock | (F2) The stock option vests 1/3 on March 28, 2025, March 28, 2026 and March 28, 2027, subject to the Eligible Director's continued service on such vesting date. |